Publication

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.

Journal Paper/Review - Feb 10, 2022

Units
PubMed
Doi
Contact

Citation
Yaghi S, Shu L, Bakradze E, Omran S, Argilés J, Amar J, Henninger N, Elnazeir M, Liberman A, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair A, Simpkins A, Trivioli G, Kung J, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman L, Mistry E, Kerrigan D, Lafever H, Nguyen T, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, ElJamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad S, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati M, Paciaroni M, Siegler J, Kamen S, Yu S, Leon Guerrero C, Atallah E, De Marchis G, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind D, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022; 53:728-738.
Type
Journal Paper/Review (English)
Journal
Stroke 2022; 53
Publication Date
Feb 10, 2022
Issn Electronic
1524-4628
Pages
728-738
Brief description/objective

A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort.